NCT00728728

Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: VA Office of Research and Development · Federal
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate adjunctive pregnenolone for patients with schizophrenia and schizoaffective disorder.

Conditions

• Schizophrenia
• Schizoaffective Disorder

Interventions

Type	Name	Description
DRUG	Dietary Supplement: Pregnenolone	Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
DIETARY_SUPPLEMENT	Placebo	Placebo

Timeline

• Start date: 2009-12-01
• Primary completion: 2015-03-01
• Completion: 2015-12-01
• First posted: 2008-08-06
• Last updated: 2017-02-10
• Results posted: 2017-02-10

Locations

1 site across 1 country: United States